Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
OT-A201 + lenalidomide
- Development stage
- Phase 1
- Lead developer
- Onward Therapeutics
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
OT-A201 + lenalidomide is an investigational **combination therapy** comprised of OT-A201, a first-in-class humanized bispecific antibody targeting two immune checkpoints, and lenalidomide, an approved immunomodulatory small molecule (IMiD) with anti-cancer and immune-enhancing properties. OT-A201 binds two different immune checkpoint antigens and possesses a functional Fc domain to facilitate antibody-dependent cell-mediated cytotoxicity (ADCC). Lenalidomide modulates the immune system and exerts anti-tumor activity by binding to cereblon in the cullin ring E3 ubiquitin ligase complex, inducing degradation of key transcription factors, inhibiting pro-inflammatory cytokines, and enhancing NK and T cell cytotoxicity. The combination is being evaluated in a Phase 1 clinical trial for relapsed/refractory hematologic malignancies and solid tumors[1][3][5][9].
- Other names
- lenalidomide
02
Targets
IKZF3 (Zinc finger protein Aiolos)CK1α (Casein kinase I alpha)CRBN (Cereblon)IKZF1 (Ikaros family zinc finger protein 1)LAG3 (Lymphocyte activation Gene-3 protein)PDCD1 (Programmed cell death protein 1 receptor)IL1A (Interleukin 1 alpha)IL12 (Interleukin-12)IL-6 (Interleukin 6)IFNG (Interferon gamma)IL-2 (Interleukin 2)TNFA (Tumor necrosis factor alpha (soluble))
Beyond the preview
Go deeper on OT-A201 + lenalidomide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on OT-A201 + lenalidomide.